Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of VX-407 in autosomal dominant polycystic kidney disease with selected PKD1 variants
2024-517393-13-00Phase 2Authorised
- Sponsor
- Vertex Pharmaceuticals
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of VX-407 in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Vertex Pharmaceuticals. Primary endpoint: Proportion of subjects with non-increase in htTKV over time. Planned start Dec 2025; status: authorised.
02
Drugs
VX-407
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2024-517393-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517393-13-00.